more_reports

The Latest Medical Devices Articles from Streetwise Reports

Medical Equipment Co. Shows Strong Profit Margin

Research Report
  ()
Despite this, the Buy-rated company remains undervalued by the markets due to ongoing business risk, noted a Leede Financial Inc. report.
Tags: Medical Devices

Intratubal Insemination Device Shown Effective, Safe

Research Report
  ()
Pregnancy rates with this "only new innovation for infertility in decades" were "impressive" in a pivotal study in women with male factor infertility, noted an H.C. Wainwright & Co. report.
Tags: Medical Devices

Developer of Medical Instruments Attracts Research Coverage

Research Report
  ()
Both of this Buy-rated company's two business divisions are contributing to topline growth, noted a Leede Financial Inc. report.
Tags: Medical Devices

Two Firms Aim To Create Functional Cure for Type 1 Diabetes

  ()
Each company is pursuing its own treatment approach to achieve insulin independence, consisting of islet cells (donor or stem cell derived), delivered into the portal vein or housed in a Cell Pouch bio-hybrid organ that is implanted in the body. Learn more about their respective programs.
Tags: Medical DevicesRegenerative Medicine

Opportunity Arises for Co. With Cell Pouch

Research Report
  ()
This medical device owner could team up with a biotech firm that just prioritized its diabetes program, noted a Leede Financial Inc. report.
Tags: Medical Devices

Revolutionary AI Tools Take Center Stage in Medical Education Symposium

  ()
Treatment.com AI Inc. (TRUE:CSE; TREIF:OTCMKTS; 939:FRA) has announced the release of its newly updated Medical Education Suite (MES). Read more to find out how this update is set to transform medical education and enhance training efficiency.
Tags: Healthcare ServicesMedical Devices

Medical Co. Ready for a Transformative F2025

Research Report
  ()
The Leede Financial Inc. analyst also noted that while F2024 is a transition year for Profound Medical Corp. (PROF:NASDAQ; PRN:TSX), F2025 is expected to be transformative for U.S. TULSA-PRO adoption. rates.
Tags: Healthcare ServicesMedical Devices

Regenerative Medicine Co. May Have Solution to Delivering Cell Treatments

  ()
This Canadian life sciences firm is developing an implantable cell-containing pouch, shown in clinical trial data thus far to be safe, well-tolerated and effective. Learn why several analysts rate the company Buy.
Tags: Regenerative MedicineMedical Devices

Revolutionizing Chronic Disease Treatment Through Regenerative Medicine

  ()
A regenerative medicine therapeutics company focused on developing technologies to address chronic diseases through a regenerative approach, Sernova Corp. (SVA:TSX.V; SEOVF:OTCMKTS; XETRA:PSH) is focused on reforming healthcare through technology. See why experts and analysts are praising this company's potential.
Tags: Medical DevicesBiotechnology / Pharmaceuticals

Trial Data Help Position Cell Pouch for Commercial Success

Research Report
  ()
The upside implied in the target price on this Canadian firm, developing regenerative medicine platform technologies, is 1,900%, noted an H.C. Wainwright & Co. report.
Tags: Medical DevicesRegenerative Medicine

Co's. Cell Pouch Performs Well in Study

Research Report
  ()
Data show the device keeps the incorporated therapeutic cells alive and functioning for at least five years, noted a Leede Financial Inc. report.
Tags: Regenerative MedicineMedical Devices

Is It Now Time To Buy This Biotech Stock?

Contributed Opinion
  ()
Technical Analyst Clive Maund shares his thoughts on Sernova Corp. (SVA:TSX.V; SEOVF:OTCMKTS; XETRA:PSH) to explain why he believes it is a good stock to accumulate, between the current price and recent lows.
Tags: Biotechnology / PharmaceuticalsMedical Devices

Implanted Cell Device Reaches 5 Year Milestone

Research Report
  ()
This pouch, loaded with pancreatic islet cells, is being evaluated in patients with insulin-dependent Type 1 diabetes, noted a Ventum Capital Markets report.
Tags: Medical DevicesRegenerative Medicine

Biotech Co. Says New Data Show Success of Type 1 Diabetes Treatment

  ()
Clinical stage biotechnology company Sernova Corp. (SVA:TSX.V; SEOVF:OTCMKTS; XETRA:PSH) has released new data that show success in using its Cell Pouch Transplant System to help Type 1 diabetes patients reach insulin independence. One author says the company is David taking on Goliath in the race for a cure.
Tags: Biotechnology / PharmaceuticalsMedical Devices

Showing Results: 1 to 14 of 14